News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

pSivida Corp (PSDV) Announces UK's National Institute for Clinical Excellence (NICE) Says Yes to ILUVIEN® in Some Patients With Diabetic Macular Edema in New Draft Guidance



6/14/2013 10:26:05 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida Corp. (NASDAQ:PSDV - News), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that the United Kingdom’s National Institute for Health and Care Excellence (NICE) issued draft guidance recommending ILUVIEN® for the treatment of pseudophakic patients (those who have undergone prior cataract surgery) with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. Following a rapid review by NICE, this recommendation proposes a change to the published guidance issued by NICE in January 2013 and takes into consideration a patient access scheme (PAS) submitted by Alimera.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES